View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 1, 2011

Pfizer acquires Icagen

Pfizer, through its wholly owned subsidiary Eclipse Acquisition, has completed the acquisition of biopharmaceutical company Icagen.

Pfizer, through its wholly owned subsidiary Eclipse Acquisition, has completed the acquisition of biopharmaceutical company Icagen.

As per the agreement, each issued and outstanding share of Icagen common stock has been converted into the right to receive $6 in cash, without interest and less any applicable withholding and transfer taxes.

Icagen is now part of Pfizer’s worldwide R&D organisation, and will be integrated into Neusentis, Pfizer’s research unit.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology